VolitionRX Limited (NYSEAMERICAN:VNRX) Stock Short Interest Declines 54.8%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 1,004,963 shares, a decline of 54.8% from the August 31st total of 2,224,050 shares. Based on an average daily trading volume, of 1,733,578 shares, the short-interest ratio is currently 0.6 days. Currently, 7.9% of the shares of the stock are short sold.

VolitionRX Price Performance

Shares of NYSEAMERICAN VNRX traded up $0.00 during mid-day trading on Wednesday, hitting $0.26. 1,164,619 shares of the stock traded hands, compared to its average volume of 3,110,406. The company has a market cap of $3.52 million, a PE ratio of -0.07 and a beta of 1.10. VolitionRX has a twelve month low of $0.23 and a twelve month high of $13.58. The firm has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $1.77.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.41 million. On average, equities research analysts anticipate that VolitionRX will post -1.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VNRX has been the topic of several research analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark restated a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.00.

About VolitionRX

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.